Job Posting, Research Scientist, DNA Sequencing
mjansen at exelixis.com
Mon Mar 8 18:10:26 EST 1999
Exelixis Pharmaceuticals, Inc. (EPI) is a rapidly growing, well-funded, privately held
biopharmaceutical company whose mission is to identify novel therapeutic targets for
drug discovery by elucidating the biochemical pathways involved in human diseases.
Our current research programs are focused on metabolic disorders, neurodegenerative
diseases, and oncology. We use a combination of invertebrate genetics (C. elegans and
Drosophila), genomics, and vertebrate biology to identify key molecules in the
pathways contributing to these disease states. EPI is also committed to developing new
approaches to the control of agricultural pest species. We are applying our core
technology in genetics and genomics to the discovery of specific targets for crop
protection and animal health. We currently have openings for talented individuals to
join our dynamic team.
Position: Associate/Research Scientist, DNA Sequencing
You will supervise daily operations at a high throughput sequencing lab while participating in
all aspects of the high throughput sequencing process. Familiarity with sequence assembly
software, automation, and troubleshooting for large-scale sequencing projects a plus.
Requirements: Ph.D. or MS with 2-4 years of prior supervisory experience. Demonstrated
leadership skills in a high volume lab; experience with automated DNA sequencers preferred.
To apply, send a cover letter referring to the specific job code(s), Curriculum Vitae
(CV), along with salary history, list of references, and publication record, if applicable,
Exelixis Pharmaceuticals, Inc.
Attn: Human Resources Department
260 Littlefield Ave.
South San Francisco, CA 94080
Tel: 650.825.2200 ñ Fax: 650.825.4240
careers at exelixis.com
Email submissions should be sent to "careers at exelixis.com" and must contain:
1. Job code(s) in the subject line of the message.
2. A text (ASCII) version of your CV in the body of the message (please do not send
More information about the Autoseq